Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2020 / Cilt: 54 - Sayı: 3

Pheochromocytoma and Paraganglioma: From Clinical Findings to Diagnosis

Pages
271–280
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Plasma free metanephrine or24-hour urinary fractionated metanephrine level is recommended as a screening test for the diagnosis of PPGL in the EndocrineSociety Clinical Practice Guideline.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The majority of pheochromocytoma (PCC) and paraganglioma (PGL) are endocrine active tumors, and they cause clinical symptomsby secreting excess one or more catecholamines (epinephrine, norepinephrine, and dopamine) and their inactive metabolites(metanephrine, normetanephrine, 3-metoxythromine).
📊
Key Findings & Data:Persistent, sometimesworsening hypertension is the most common finding and occurs in 80-90% of the patients.
💡
Conclusion & Impact:Plasma free metanephrine or24-hour urinary fractionated metanephrine level is recommended as a screening test for the diagnosis of PPGL in the EndocrineSociety Clinical Practice Guideline.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

The majority of pheochromocytoma (PCC) and paraganglioma (PGL) are endocrine active tumors, and they cause clinical symptomsby secreting excess one or more catecholamines (epinephrine, norepinephrine, and dopamine) and their inactive metabolites(metanephrine, normetanephrine, 3-metoxythromine). Although signs and symptoms regarding excess catecholamine oftendevelop in PCC and PGL (PPGL), non-functional PPGLs may present with local compression symptoms. Persistent, sometimesworsening hypertension is the most common finding and occurs in 80-90% of the patients. Classically defined symptom triad;headache, sweating and palpitations are seen in only 25% of the patients with PCC. The difference of clinical symptoms may berelated to the tumor secretion, epinephrine or norepinephrine. All patients with signs and symptoms suggestive of catecholamineexcess should be screened by biochemical tests regardless of whether they have hypertension or not. Not all patients with newlydiagnosed hypertension need to be screened, but only patients with additional tips for catecholamine excess should be screened.Approximately 20% of the PPGLs are diagnosed in childhood, and the male/female ratio is 2/1. 60-90% of pediatric patients presentwith hypertension. PPGL in pregnancy is rare, and the estimated incidence ranges between 1/15000-1/54000. Although earlydiagnosis is the most important factor in preventing mortality, diagnosis is not as easy as it is a rare condition. Hypertension is acommon complication in pregnancy, occurring in 5-10%. Computed tomography should not be used as the imaging method duringpregnancy; the first choice is magnetic resonance imaging with gadolinium or without contrast. Plasma free metanephrine or24-hour urinary fractionated metanephrine level is recommended as a screening test for the diagnosis of PPGL in the EndocrineSociety Clinical Practice Guideline. In suspicious situations, tests should be repeated. Since 40% of these patients have germlinemutations, genetic tests are recommended for all patients with PPGL regardless of family history and age. Preoperative knowledgeof germline mutations affects the surgical approach and the extent of adrenalectomy. After the biochemical diagnosis is made inPPGL, the tumor is localized with imaging methods to make the operation plan. In this review, we aimed to evaluate the clinicalfindings, diagnostic tests, and imaging studies for tumor localization in PPGL.

🔖

Cite This Article

AYGÜN, N., ULUDAĞ, M. (2020). Pheochromocytoma and Paraganglioma: From Clinical Findings to Diagnosis. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 54 - Sayı: 3, 271–280. https://ajindex.com/articles/363394

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Tevosian SG, Ghayee HK. Pheochromocytomas and Paragangliomas. Endocrinol Metab Clin North Am 2019;48:727–50
  2. Patel D, Phay JE, Yen TWF, Dickson PV, Wang TS, Garcia R, et al. Update on Pheochromocytoma and Paraganglioma from the SSO Endocrine/Head and Neck Disease-Site Work Group. Part 1 of 2: Advances in Pathogenesis and Diagnosis of Pheochromocytoma and Paraganglioma. Ann Surg Oncol 2020;27:1329–37
  3. Aygun N, Uludag M. Pheochromocytoma and Paraganglioma: From Epidemiology to Clinical Findings. Sisli Etfal Hastan Tip Bul 2020;54:159–68
  4. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al; Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99:1915–42
  5. Zuber SM, Kantorovich V, Pacak K. Hypertension in pheochromocytoma: characteristics and treatment. Endocrinol Metab Clin North Am 2011;40:295–311
  6. Kiernan CM, Solórzano CC. Pheochromocytoma and Paraganglioma: Diagnosis, Genetics, and Treatment. Surg Oncol Clin N Am 2016;25:119–38
  7. Frunzac RW, Grant CS. Pheochromocytoma. In: Clark OH, Duh QY, Kebebew E, Gosnell JE, Shen WT, editors. Textbook of Endocrine Surgery. 3rd ed. Jaypee Brothers Medical Publishers; 2016. p. 1047–67. 8. van Berkel A, Lenders JW, Timmers HJ. Diagnosis of endocrine disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma. Eur J Endocrinol 2014;170:R109–19
  8. Bholah R, Bunchman TE. Review of Pediatric Pheochromocytoma and Paraganglioma. Front Pediatr 2017;5:155
  9. Bausch B, Wellner U, Bausch D, Schiavi F, Barontini M, Sanso G, et al. Long-term prognosis of patients with pediatric pheochromocytoma. Endocr Relat Cancer 2013;21:17–25
  10. Lenders JWM, Langton K, Langenhuijsen JF, Eisenhofer G. Pheochromocytoma and Pregnancy. Endocrinol Metab Clin North Am 2019;48:605–17
  11. Lenders JW. Pheochromocytoma and pregnancy: a deceptive connection. Eur J Endocrinol 2012;166:143–50
  12. Biggar MA, Lennard TW. Systematic review of phaeochromocytoma in pregnancy. Br J Surg 2013;100:182–90
  13. Wing LA, Conaglen JV, Meyer-Rochow GY, Elston MS. Paraganglioma in Pregnancy: A Case Series and Review of the Literature. J Clin Endocrinol Metab 2015;100:3202–9
  14. Vest AR, Cho LS. Hypertension in pregnancy. Curr Atheroscler Rep 2014;16:395. 16. van der Weerd K, van Noord C, Loeve M, Knapen MFCM, Visser W, de Herder WW, et al. Endocrinology in pregnancy: Pheochromocytoma in pregnancy: case series and review of liter